Skip to main content
Equibles
IKT logo

IKT · Inhibikase Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track IKT — free

Use IKT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IKT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.00 +0.00 (+0.00%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Market Cap
$287.44M
Shares
139.54M
Volume · Oct 5 407.49K Avg daily vol (3M) 672.67K

Inhibikase Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Inhibikase Therapeutics, Inc. (IKT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼99.5% $6,552 −$4.64M '22 Q2 22-06-30 ▼97.8% $7,291 −$4.49M '22 Q3 22-11-17 ▲3169.9% $63,566 −$4.28M '22 Q4 22-12-31 ▲40.2% $64,521 −$4.48M '23 Q1 23-03-31 ▲1676.7% $116,410 −$5.78M '23 Q2 23-06-30 ▲991.3% $79,569 −$4.60M '23 Q3 23-09-30 ▼100% $1 −$4.18M '23 Q4 23-12-31 ▼100% $ −$4.65M '24 Q1 24-03-31 ▼100% $ −$4.96M '24 Q2 24-06-30 ▼100% $ −$12.13M '24 Q4 25-03-27 · $ −$13.68M '25 Q1 25-05-14 · $ −$9.92M '25 Q2 25-08-14 · $ −$11.93M '25 Q3 25-11-14 · $ −$16.38M '26 Q1 26-05-12 LATEST · $ −$19.59M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
Inhibikase Therapeutics, Inc. (IKT) Q2 2026 Earnings Call
Revenue
$
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Inhibikase Therapeutics, Inc. (IKT) Q1 2026 Earnings Call
Revenue
$
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Inhibikase Therapeutics, Inc. (IKT) Q4 2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Inhibikase Therapeutics, Inc. (IKT) Q3 2025 Earnings Call
Revenue
$
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Inhibikase Therapeutics, Inc. (IKT) Q2 2025 Earnings Call
Revenue
$
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Inhibikase Therapeutics, Inc. (IKT) Q1 2025 Earnings Call
Revenue
$
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inhibikase Therapeutics, Inc. (IKT) Q4 2024 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-06-30
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
Positive tone IkT-001Pro in pulmonary arterial hypertension Cash position and capital needs Biomarker and diagnostic tools
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
Confident tone Pulmonary Arterial Hypertension (PAH) Opportunity Alpha-Synuclein Biomarker and Antibody Development Capital Needs and Financing Constraints
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Revenue
$1*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Inhibikase Therapeutics, Inc. (IKT) Q3 2023 Earnings Call Transcript
Revenue
$79,569
▲ 991.3% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
Revenue
$116,410
▲ 1676.7% YoY
Diluted EPS
$-1.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call Transcript
Revenue
$64,521
▲ 40.2% YoY
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Inhibikase Therapeutics, Inc. (IKT) Q4 2022 Earnings Call Transcript
Revenue
$63,566*
▲ 3169.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-17
Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript
Revenue
$7,291
▼ 97.8% YoY
Diluted EPS
$-1.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Inhibikase Therapeutics, Inc. (IKT) Q2 2022 Earnings Call Transcript
Revenue
$6,552
▼ 99.5% YoY
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Inhibikase Therapeutics, Inc. (IKT) Q1 2022 Earnings Call Transcript
Revenue
$46,031
▼ 96.7% YoY
Diluted EPS
$-1.08
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Inhibikase Therapeutics, Inc. (IKT) Q4 2021 Earnings Call Transcript
Revenue
$1,944*
▼ 98.9% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q1
2021-04-01
Inhibikase Therapeutics, Inc. (IKT) Q1 2021 Earnings Call
Revenue
$1.41M
▲ 419.7% YoY
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–19 of 19 webcasts
Key facts CIK 1750149 CUSIP 45719W205 13F (30d) 2 filings 2 filers Visit website Investor relations